2020 May 1, 2020
ACTT Trial Results Indicate Remdesivir’s Efficacy Against Covid-19
1 min read
ACTT Trial Results Indicate Remdesivir’s Efficacy Against Covid-19
The National Institutes of Health released interim data from the Phase 3 ACTT trial, which explores remdesivir for the treatment of Covid-19. Interim findings show remdesivir decreased the patients’ recovery time by 31% over placebo (see link below).
Gayathri Raghupathy, Ph.D. provides insight on these results, stating that “while it may not be a cure, these results are very promising and can help advance the fight against Covid-19.”
The image below outlines the timeline and details of the clinical trial.